|
1.
|
|
3 p, 192.6 KB |
Challenges and Solutions for Collecting and Analyzing Real World Data : The Eric CLL Database as an Illustrative Example
/
Chatzidimitriou, Anastasia (Karolinska Institutet, Stockholm) ;
Minga, Eva (Institute of Applied Biosciences, Thessaloniki) ;
Chatzikonstantinou, Thomas (G. Papanikolaou Hospital, Thessaloniki) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Stamatopoulos, Kostas (Karolinska Institutet, Stockholm) ;
Ghia, Paolo (Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan) ;
Universitat Autònoma de Barcelona
2020 -  10.1097/HS9.0000000000000425
HemaSphere, Vol. 4 (september 2020)
|
|
|
2.
|
|
10 p, 631.8 KB |
Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL : analysis from the iLLUMINATE study
/
Greil, Richard (Salzburg Cancer Research Institute-CCCIT, Cancer Cluster Salzburg. IIIrd Medical Department Paracelsus Medical University) ;
Tedeschi, Alessandra (Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Anz, Bertrand (Tennessee Oncology. Department of Medical Oncology) ;
Larratt, Loree (University of Alberta Hospital. Department of Clinical Hematology) ;
Simkovic, Martin (University Hospital Hradec Kralove (República Txeca)) ;
Gill, Devinder (Princess Alexandra Hospital. Department of Clinical Hematology) ;
Gribben, John G. (Queen Mary University of London, Barts Cancer Institute. Centre for Haemato-Oncology) ;
Flinn, Ian W. (Medical Oncology, Sarah Cannon Research Institute/Tennessee Oncology. Center for Blood Cancers) ;
Wang, Zhengyuan (Pharmacyclics LLC, an AbbVie Company. Translational Medicine) ;
Cheung, Leo W. K. (Pharmacyclics LLC, an AbbVie Company. Translational Medicine) ;
Nguyen, Aaron N. (Pharmacyclics LLC, an AbbVie Company. Translational Medicine) ;
Zhou, Cathy (Pharmacyclics LLC, an AbbVie Company. Biostatistics) ;
Styles, Lori (Pharmacyclics LLC, an AbbVie Company. Clinical Science) ;
Demirkan, Fatih (Dokuz Eylül University. Department of Hematology) ;
Universitat Autònoma de Barcelona
The online version contains supplementary material available at 10. 1007/s00277-021-04536-6.
2021 - 10.1007/s00277-021-04536-6
Annals of Hematology, Vol. 100 (may 2021) , p. 1733-1742
|
|
|
3.
|
|
12 p, 1.8 MB |
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL : 5 years of follow-up from the phase 3 RESONATE-2 study
/
Burger, Jan A. (University of Texas MD Anderson Cancer Center. Department of Leukemia) ;
Barr, Paul M. (Wilmot Cancer Institute, University of Rochester Medical Center) ;
Robak, Tadeusz (Medical University of Lodz, Copernicus Memorial Hospital) ;
Owen, Carolyn (University of Calgary. Tom Baker Cancer Centre) ;
Ghia, P (Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele) ;
Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy) ;
Bairey, Osnat (Tel Aviv University. Rabin Medical Center, Petah Tikva, Israel and Sackler Faculty of Medicine) ;
Hillmen, Peter (University of Leeds. The Leeds Teaching Hospitals, St. James Institute of Oncology) ;
Coutre, Steven E. (Stanford University School of Medicine. Stanford Cancer Center) ;
Devereux, Stephen (NHS Foundation Trust. Kings College Hospital) ;
Grosicki, Sebastian (Silesiam Medical University. Department of Hematology and Cancer Prevention) ;
McCarthy, Helen (Royal Bournemouth General Hospital (Dorset, Regne Unit)) ;
Simpson, David (North Shore Hospital) ;
Offner, Fritz (Universitair Ziekenhuis Gent) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Dai, Sandra (Pharmacyclics LLC, an AbbVie Company) ;
Lal, Indu (Pharmacyclics LLC, an AbbVie Company) ;
Dean, James P. (Pharmacyclics LLC, an AbbVie Company) ;
Kipps, Thomas J. (UCSD Moores Cancer Center) ;
Universitat Autònoma de Barcelona
RESONATE-2 is a phase 3 study of first-line ibrutinib versus chlorambucil in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Patients aged ≥65 years (n = 269) were randomized 1:1 to once-daily ibrutinib 420 mg continuously or chlorambucil 0. [...]
2019 - 10.1038/s41375-019-0602-x
Leukemia, Vol. 34 (october 2019) , p. 787-798
|
|
|
4.
|
|
11 p, 1.8 MB |
Final analysis from RESONATE : Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
/
Munir, T. (St. James's Hospital ( Dublín, Irlanda)) ;
Brown, J.R. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
O'Brien, Susan (UC Irvine. Chao Family Comprehensive Cancer Center) ;
Barrientos, J.C. (Northwell Health Cancer Institute (Estats Units d'Amèrica)) ;
Barr, P.M. (Wilmot Cancer Institute. University of Rochester Medical Center) ;
Reddy, N.M. (Vanderbilt-Ingram Cancer Center) ;
Coutre, Steven E (Stanford Cancer Center. Stanford University School of Medicine) ;
Tam, C.S. (Peter MacCallum Cancer Centre. St. Vincent's Hospital and University of Melbourne) ;
Mulligan, S.P. (Royal North Shore Hospital) ;
Jaeger, U. (Division of Hematology and Hemostaseology. Medical University of Vienna) ;
Kipps, T.J. (UCSD Moores Cancer Center) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Montillo, M. (Niguarda Ca' Granda Hospital) ;
Burger, J.A. (Department of Leukemia. University of Texas MD Anderson Cancer Center) ;
Byrd, J.C. (The Ohio State University Comprehensive Cancer Center) ;
Hillmen, Peter (The Leeds Teaching Hospitals. St. James Institute of Oncology) ;
Dai, S. (Pharmacyclics LLC. an AbbVie Company) ;
Szoke, A. (Pharmacyclics LLC. an AbbVie Company) ;
Dean, J.P. (Pharmacyclics LLC. an AbbVie Company) ;
Woyach, J.A. (The Ohio State University Comprehensive Cancer Center) ;
Universitat Autònoma de Barcelona
Ibrutinib, a once-daily oral inhibitor of Bruton's tyrosine kinase, is approved in the United States and Europe for treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). [...]
2019 - 10.1002/ajh.25638
American Journal of Hematology, Vol. 94 Núm. 12 (january 2019) , p. 1353-1363
|
|
|
5.
|
|
11 p, 693.2 KB |
ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation
/
Malcikova, J. (Brno, Czech Republic) ;
Tausch, E. (Ulm, Germany) ;
Rossi, Davide (Bellinzona, Switzerland) ;
Sutton, L. A. (Stockholm, Sweden) ;
Soussi, T. (Stockholm, Sweden) ;
Zenz, T. (Zürich, Switzerland) ;
Kater, A. P. (Amsterdam, The Netherlands) ;
Niemann, C. U. (Copenhagen, Denmark) ;
González De Castro, David (Belfast, UK) ;
Davi, F. (Paris, France) ;
Gonzalez Diaz, M. (Salamanca, Spain) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Gaidano, G. (Novara, Italy) ;
Stamatopoulos, K. (Thessaloniki, Greece) ;
Rosenquist, R. (Stockholm, Sweden) ;
Stilgenbauer, S. (Ulm, Germany) ;
Ghia, P. (Milan, Italy) ;
Pospisilova, S. (Brno, Czech Republic) ;
Universitat Autònoma de Barcelona
In chronic lymphocytic leukemia (CLL), TP53 gene defects, due to deletion of the 17p13 locus and/or mutation(s) within the TP53 gene, are associated with resistance to chemoimmunotherapy and a particularly dismal clinical outcome. [...]
2018 - 10.1038/s41375-017-0007-7
Leukemia, Vol. 32 (february 2018) , p. 1070-1080
|
|
|
6.
|
|
7 p, 4.6 MB |
Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ATM FISH deletions
/
Puiggros, Anna (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Collado, Rosa (Hospital General Universitario de Valencia) ;
Calasanz, Maria José (Servicio de Citogenética, Departamento de Genética, Universidad de Navarra, Pamplona, Spain) ;
Ortega, Margarita (Hospital Universitari Vall d'Hebron) ;
Ruiz-Xivillé, Neus (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Rivas-Delgado, Alfredo (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Luño, Elisa (Servicio de Hematología, Hospital Universitario Central de Asturias, Oviedo, Spain) ;
González, Teresa (Fundación Pública Galega de Medicina Xenómica) ;
Navarro, Blanca (Hospital Clínic Universitari (València)) ;
García-Malo, MaDolores (Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, IMIB-Arrixaca, Murcia, Spain) ;
Valiente, Alberto (Complejo Hospitalario de Navarra) ;
Hernández, José Ángel (Hospital Universitario Infanta Leonor) ;
Ardanaz, María Teresa (Servicio de Hematología, Hospital Txagorritxu, Vitoria, Spain) ;
Piñan, María Ángeles (Hospital Universitario de Cruces (Barakaldo, País Basc)) ;
Blanco, María Laura (Institut d'Investigació Biomèdica Sant Pau) ;
Hernández-Sánchez, María (Hospital Universitario de Salamanca. Centro de Investigación del Cáncer) ;
Batlle-López, Ana (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Salgado Sánchez, Rocío Nieves (Laboratorio de Citogenética, Servicio de Hematología, Fundación Jiménez Díaz, Madrid, Spain) ;
Salido, Marta (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Ferrer, Ana (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Abrisqueta, Pau (Hospital Universitari Vall d'Hebron) ;
Gimeno, Eva (Hospital del Mar (Barcelona, Catalunya)) ;
Abella Monreal, Eugenia (Hospital del Mar (Barcelona, Catalunya)) ;
Ferrá, Christelle (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Terol, María José (Hospital Clínic Universitari (València)) ;
Ortuño, Francisco (Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, IMIB-Arrixaca, Murcia, Spain) ;
Costa, Dolors (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Carbonell, Félix (Hospital General Universitario de Valencia) ;
Bosch José, Francesc Xavier (Hospital Universitari Vall d'Hebron) ;
Delgado, Julio (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Espinet i Solà, Blanca (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Universitat Autònoma de Barcelona
Genomic complexity identified by chromosome banding analysis (CBA) predicts a worse clinical outcome in CLL patients treated either with standard or new treatments. Herein, we analyzed the clinical impact of complex karyotypes (CK) with or without high-risk FISH deletions (ATM and/or TP53, HR-FISH) in a cohort of 1045 untreated MBL/CLL patients. [...]
2017 - 10.18632/oncotarget.17350
Oncotarget, Vol. 8 (april 2017) , p. 54297-54303
|
|
|
7.
|
|
7 p, 550.2 KB |
Impact of Cyclosporine Levels on the Development of Acute Graft versus Host Disease after Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation
/
Garcia Cadenas, Irene (Institut d'Investigació Biomèdica Sant Pau) ;
Valcarcel, David (Hospital Universitari Vall d'Hebron) ;
Martino, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Piñana, J. L. (Hospital Clínic Universitari (València)) ;
Barba, Pere (Hospital Universitari Vall d'Hebron) ;
Novelli, Silvana (Institut d'Investigació Biomèdica Sant Pau) ;
Esquirol, Albert (Institut d'Investigació Biomèdica Sant Pau) ;
Garrido, Ana (Institut d'Investigació Biomèdica Sant Pau) ;
Saavedra, Silvana (Institut d'Investigació Biomèdica Sant Pau) ;
Granell, Miquel (Institut d'Investigació Biomèdica Sant Pau) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Briones Meijide, Javier (Institut d'Investigació Biomèdica Sant Pau) ;
Brunet, Salut (Institut d'Investigació Biomèdica Sant Pau) ;
Sierra, Jorge (Institut d'Investigació Biomèdica Sant Pau) ;
Universitat Autònoma de Barcelona
We analyze the impact of cyclosporine (CsA) levels in the development of acute graft-versus-host disease (aGVHD) after reduced intensity conditioning allogeneic hematopoietic transplantation (allo-RIC). [...]
2014 - 10.1155/2014/620682
Mediators of Inflammation, Vol. 2014 (january 2014)
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
